



Nov 21, 2022

An analysis of Relative Telomere Length (RTL) during peri-operative chemotherapy in patients with operable gastric or gastro-oesophageal junction adenocarcinoma

DOI

<https://dx.doi.org/10.17504/protocols.io.ca5csg2w>

Jeff Evans¹, Nicol Keith¹, James Paul¹

¹School of Cancer Sciences, University of Glasgow, Glasgow, UK



Caroline Kelly

Create & collaborate more with a free account

Edit and publish protocols, collaborate in communities, share insights through comments, and track progress with run records.

Create free account

OPEN  ACCESS



DOI: <https://dx.doi.org/10.17504/protocols.io.ca5csg2w>

Protocol Citation: Jeff Evans, Nicol Keith, James Paul 2022. An analysis of Relative Telomere Length (RTL) during peri-operative chemotherapy in patients with operable gastric or gastro-oesophageal junction adenocarcinoma. **protocols.io** <https://dx.doi.org/10.17504/protocols.io.ca5csg2w>

License: This is an open access protocol distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited



Protocol status: Working

Created: June 11, 2022

Last Modified: November 21, 2022

Protocol Integer ID: 64388

Keywords: analysis of relative telomere length, relative telomere length, analyse relative telomere length, operative chemotherapy in patient, chemotherapy in patient, operative chemotherapy, tumour response, oesophageal junction adenocarcinoma, chemotherapy, oesophageal adenocarcinoma, lower oesophageal adenocarcinoma, comparison of the radiological staging, tumour, repeat radiological staging in the event, staging of the primary tumour, pathological staging at subsequent resection, radiological staging, progressive disease so that the tumour, primary tumour, cellular senescence in blood sample, patient outcome, operable gastric

Funders Acknowledgements:

Cancer Research UK

Grant ID: A25174

Chief Scientist Office, Scotland

Grant ID: A15584

Abstract

OBJECTIVES

The primary objective of this study is:

(a) to analyse Relative Telomere Length (RTL) in blood samples taken from patients during peri-operative chemotherapy for operable gastric or gastro-oesophageal junction adenocarcinoma. This will allow us to determine if the baseline (pre-treatment) RTL correlates with patient outcome as measured by relapse-free (RFS) and overall survival (OS).

The secondary objectives of this study are:

(a) to determine if the baseline (pre-treatment) RTL correlates with “tumour response” as measured by down-staging of the primary tumour with the pre-operative component of chemotherapy (comparison of the radiological staging at diagnosis, before pre-operative chemotherapy, with pathological staging at subsequent resection or with repeat radiological staging in the event of progressive disease so that the tumour is inoperable).

(b) to analyse changes in markers associated with cellular senescence in blood samples taken from patients during peri-operative chemotherapy for operable gastric or gastro-oesophageal junction adenocarcinoma. These will include cathelicidin-related antimicrobial protein (CRAMP), EF-1a, stathmin, and chitinase 3-like protein 3.

The tertiary (exploratory) objectives of this study are:

(a) to analyse changes in CK-18 in blood samples taken from patients during peri-operative chemotherapy for operable gastric or gastro-oesophageal junction adenocarcinoma as a marker of drug-induced cell death by apoptosis.

(b) to analyse changes in senescence-associated micro-RNAs in blood samples taken from patients during peri-operative chemotherapy for operable gastric or gastro-oesophageal junction adenocarcinoma.

STUDY DESIGN

This will be a multi-centre, open, non-randomised study. Eligible patients will be those with operable gastric, gastro-oesophageal junction or lower oesophageal adenocarcinoma who are about to undergo peri-operative chemotherapy with either the ECF/EOF or ECX/EOX (epirubicin, Cisplatin/oxaliplatin and capecitabine/5-FU) regimens. Additionally, patients randomised in the NCRN STO3 study to receive ECX + bevacizumab will also be eligible.

Attachments



[GI160_RTL_PeriOp_v5....](#)

518KB

